Machine Learning used in real-world analysis of COVID-19 pharmacotherapy

• Real-world data generated from clinical practice can be used to analyse the real-world evidence (RWE) of COVID-19 pharmacotherapy and validate the results of randomised clinical trials (RCTs)
• 5244 and 1312 COVID-19 hospital admissions – dated between January 2020 and January 2021 from 10 health departments, were used respectively for training and validation of separate treatment-effect models for remdesivir, corticosteroids, tocilizumab, lopinavir-ritonavir, azithromycin and chloroquine/hydroxychloroquine
• Machine Learning (ML) methods are suitable tools toward RWE analysis of COVID-19 pharmacotherapies. Results obtained reproduce published results on RWE and validate the results from RCTs

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: AUG2021BS001